{"id":3715,"date":"2026-03-02T21:32:21","date_gmt":"2026-03-02T21:32:21","guid":{"rendered":"https:\/\/slipstream-it.local\/resources\/slipstream-co-redige-la-premiere-etude-complete-sur-les-couts-de-la-telangiectasie-hemorragique-hereditaire-dans-lamerican-journal-of-hematology\/"},"modified":"2026-06-19T01:31:52","modified_gmt":"2026-06-19T01:31:52","slug":"slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology","status":"publish","type":"resource","link":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","title":{"rendered":"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l’American Journal of Hematology"},"content":{"rendered":"
\n\n \n \n \n
\n
\n
\n\n \n

\n Communiqu\u00e9 de presse <\/p>\n \n

\n Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology <\/h1>\n \n \n \n \n \n <\/div>\n <\/div>\n <\/div>\n<\/section>\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

Blue Bell, Pennsylvanie \u2013 10 juillet 2025<\/strong> \u2013 Slipstream, partenaire technologique de confiance au service de l\u2019industrie pharmaceutique et biopharmaceutique, est fier d\u2019annoncer sa co-signature d\u2019une \u00e9tude r\u00e9volutionnaire sur la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire (HHT), r\u00e9cemment publi\u00e9e dans l\u2019American Journal of Hematology<\/em>.<\/p>\n\n\n\n

L\u2019\u00e9tude, \u00ab Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia \u00bb<\/em>, est la plus vaste \u00e9tude jamais men\u00e9e sur des patients atteints de HHT, incluant plus de 24\u202f000 patients vivant avec ce trouble h\u00e9morragique rare et h\u00e9r\u00e9ditaire. La recherche r\u00e9v\u00e8le que, dans cet \u00e9chantillon, les co\u00fbts m\u00e9dicaux directs li\u00e9s \u00e0 la HHT ont d\u00e9pass\u00e9 450 millions de dollars par an aux \u00c9tats-Unis, principalement en raison du traitement des complications li\u00e9es aux saignements, notamment l\u2019an\u00e9mie ferriprive. <\/p>\n\n\n\n

<\/h2>\n\n\n\n

\u00ab<\/strong>En tirant parti de la Healthcare Map\u00ae<\/sup> de Komodo Health, qui comprend des donn\u00e9es de plus de 330 millions de patients am\u00e9ricains, nous avons pu caract\u00e9riser une maladie rare dont l\u2019histoire naturelle et la charge n\u2019avaient jamais \u00e9t\u00e9 clairement d\u00e9finies ni pleinement comprises\u00bb<\/strong>, a d\u00e9clar\u00e9 Tracy J. Mayne, PhD<\/strong><\/strong>, vice-pr\u00e9sidente senior des affaires r\u00e9glementaires et de la recherche en sciences de la vie chez Slipstream. \u00ab<\/strong>Nous savons d\u00e9sormais que pr\u00e8s de 60 % des patients diagnostiqu\u00e9s avec une HHT pr\u00e9sentent des saignements si s\u00e9v\u00e8res qu\u2019ils provoquent une an\u00e9mie, et qu\u2019une part importante de ces patients re\u00e7oit fr\u00e9quemment du fer IV et\/ou des transfusions de globules rouges. La charge, tant pour les patients que pour le syst\u00e8me de sant\u00e9, est \u00e9norme, avec des implications majeures pour le plaidoyer et le d\u00e9veloppement de m\u00e9dicaments.\u00bb<\/strong> <\/p>\n\n\n\n

L\u2019\u00e9quipe de recherche, qui comprend des collaborateurs du Massachusetts General Hospital, de Cure HHT et de Diagonal Therapeutics, a utilis\u00e9 les donn\u00e9es de r\u00e9clamations en vie r\u00e9elle de Komodo afin d\u2019\u00e9valuer la charge \u00e9conomique de la maladie dans une cohorte de plus de 24\u202f000 patients en 2022 et 2023.<\/p>\n\n\n\n

Les principales conclusions de la publication comprennent :<\/p>\n\n\n\n

\u00c0 noter que la pr\u00e9valence de la transplantation h\u00e9patique chez les patients atteints de HHT, r\u00e9sultant de complications li\u00e9es aux MAV h\u00e9patiques, \u00e9tait 40 fois plus \u00e9lev\u00e9e que dans la population g\u00e9n\u00e9rale am\u00e9ricaine.<\/p>\n\n\n\n

Les co\u00fbts par patient et par an (PPPY) pour les personnes vivant avec une HHT sont comparables \u00e0 ceux d\u2019autres maladies rares et fortement consommatrices de ressources, voire les d\u00e9passent.<\/p>\n\n\n\n

Les saignements et leurs cons\u00e9quences ont \u00e9t\u00e9 identifi\u00e9s comme les principaux facteurs de co\u00fbts de sant\u00e9.<\/p>\n\n\n\n

Les co\u00fbts moyens PPPY pour l\u2019ensemble des patients atteints de HHT \u00e9taient >19\u202f000 $ sur 2022 et 2023, soit environ 20 % de plus que ceux de la dr\u00e9panocytose.<\/p>\n\n\n\n

Les patients atteints de HHT pr\u00e9sentant une an\u00e9mie, tout en repr\u00e9sentant pr\u00e8s de 60 % de la population de patients HHT, \u00e9taient responsables d\u2019environ 80 % des co\u00fbts m\u00e9dicaux directs.<\/p>\n\n\n\n

\u00ab<\/strong>Slipstream a \u00e9t\u00e9 fond\u00e9e sur la conviction que la technologie doit permettre \u00e0 l\u2019industrie des sciences de la vie d\u2019aller plus vite, de travailler plus intelligemment et d\u2019op\u00e9rer plus efficacement\u00bb<\/strong>, a d\u00e9clar\u00e9 Brandon McKay<\/strong>, directeur g\u00e9n\u00e9ral de Slipstream. \u00ab<\/strong>Des \u00e9tudes comme celle-ci d\u00e9montrent comment les bonnes donn\u00e9es, associ\u00e9es \u00e0 la bonne expertise, peuvent red\u00e9finir ce qui est possible en mati\u00e8re de sant\u00e9. Cette collaboration illustre exactement le type de travail que nous cherchons \u00e0 r\u00e9aliser, en nous associant \u00e0 des innovateurs de tout l\u2019\u00e9cosyst\u00e8me pour lib\u00e9rer la puissance des donn\u00e9es en vie r\u00e9elle et des plateformes num\u00e9riques. Notre objectif est toujours d\u2019acc\u00e9l\u00e9rer l\u2019impact l\u00e0 o\u00f9 il compte le plus, en am\u00e9liorant les r\u00e9sultats pour les patients.\u00bb<\/strong> <\/p>\n\n\n\n

Cette \u00e9tude majeure apporte des preuves essentielles du niveau \u00e9lev\u00e9 de besoins non satisfaits chez les patients vivant avec une HHT, qui disposent de peu d\u2019options th\u00e9rapeutiques et d\u2019aucun m\u00e9dicament approuv\u00e9 modifiant la maladie ou capable d\u2019en ralentir ou d\u2019en arr\u00eater la progression. Cette \u00e9tude renforce l\u2019argumentaire en faveur de futurs d\u00e9veloppements th\u00e9rapeutiques et illustre la valeur que les preuves en vie r\u00e9elle et la base de donn\u00e9es de Komodo Health apportent au domaine des maladies rares. <\/p>\n\n\n\n

L\u2019article complet est disponible en ligne via l\u2019American Journal of Hematology<\/em> : https:\/\/doi.org\/10.1002\/ajh.27756<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

\u00c0 propos de Slipstream<\/strong>Slipstream est un partenaire technologique de confiance au service exclusif de l\u2019industrie des sciences de la vie. Notre \u00e9quipe mondiale apporte une expertise sectorielle approfondie et des solutions pragmatiques de bout en bout qui simplifient les d\u00e9fis complexes sur l\u2019ensemble du cycle de vie des produits. Nous livrons avec rapidit\u00e9, conformit\u00e9 et anticipation \u2014 en permettant \u00e0 nos clients d\u2019acc\u00e9l\u00e9rer la recherche, d\u2019optimiser les d\u00e9lais de mise sur le march\u00e9 et d\u2019am\u00e9liorer les r\u00e9sultats pour les patients, afin que la technologie suive le rythme de leur mission qui change des vies. En savoir plus sur Slipstream IT<\/a><\/p>\n\n\n\n

\u00c0 propos de la pratique Digital CRO de Slipstream<\/strong>La pratique Digital CRO de Slipstream fait progresser le d\u00e9veloppement de m\u00e9dicaments en utilisant des donn\u00e9es en vie r\u00e9elle et les approches actuelles de data science afin de cr\u00e9er des contr\u00f4les externes\/synth\u00e9tiques et des hybrides vie r\u00e9elle\/placebo comme base principale d\u2019approbation pour des m\u00e9dicaments d\u00e9velopp\u00e9s pour traiter des maladies rares. En tant que leader du march\u00e9 des plateformes num\u00e9riques pharmaceutiques, Slipstream associe une expertise th\u00e9rapeutique approfondie \u00e0 une exp\u00e9rience r\u00e9glementaire en vie r\u00e9elle et \u00e0 une technologie de pointe pour aider les entreprises sp\u00e9cialis\u00e9es dans les maladies rares \u00e0 obtenir une approbation plus rapidement et \u00e0 un co\u00fbt nettement r\u00e9duit. En s\u2019appuyant sur de vastes bases de donn\u00e9es nationales, Slipstream aide \u00e9galement \u00e0 l\u2019identification des sites et au recrutement pour les essais sur les maladies rares. En savoir plus sur notre pratique Digital CRO leader du march\u00e9<\/a><\/p>\n<\/div>\n\n\n\n

<\/div>\n<\/div>\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Blue Bell, Pennsylvanie \u2013 10 juillet 2025 \u2013 Slipstream, partenaire technologique de confiance au service de l\u2019industrie pharmaceutique et biopharmaceutique, est fier d\u2019annoncer sa co-signature d\u2019une \u00e9tude r\u00e9volutionnaire sur la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire (HHT), r\u00e9cemment publi\u00e9e dans l\u2019American Journal of Hematology. L\u2019\u00e9tude, \u00ab Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia \u00bb, est […]<\/p>\n","protected":false},"author":6,"featured_media":3100,"template":"","resource_type":[87],"business_need":[111,115,119,123],"service_type":[13],"topic":[131],"class_list":["post-3715","resource","type-resource","status-publish","has-post-thumbnail","hentry","resource_type-article-fr","business_need-emerging-biotech-fr","business_need-large-pharma-fr","business_need-rare-disease-innovators-fr","business_need-small-mid-sized-healthcare-fr","service_type-digital-cro-offerings","topic-clinical-it-solutions-fr"],"acf":[],"yoast_head":"\nSlipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology > Slipstream LS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology\" \/>\n<meta property=\"og:description\" content=\"Blue Bell, Pennsylvanie \u2013 10 juillet 2025 \u2013 Slipstream, partenaire technologique de confiance au service de l\u2019industrie pharmaceutique et biopharmaceutique, est fier d\u2019annoncer sa co-signature d\u2019une \u00e9tude r\u00e9volutionnaire sur la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire (HHT), r\u00e9cemment publi\u00e9e dans l\u2019American Journal of Hematology. L\u2019\u00e9tude, \u00ab Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia \u00bb, est […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/\" \/>\n<meta property=\"og:site_name\" content=\"Slipstream LS\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-19T01:31:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png\" \/>\n\t<meta property=\"og:image:width\" content=\"809\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/\",\"name\":\"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology > Slipstream LS\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/hht-pr.png\",\"datePublished\":\"2026-03-02T21:32:21+00:00\",\"dateModified\":\"2026-06-19T01:31:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/hht-pr.png\",\"contentUrl\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/hht-pr.png\",\"width\":809,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resources\",\"item\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/resources\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l’American Journal of Hematology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/\",\"name\":\"Slipstream\",\"description\":\"Life sciences, accelerated. Expertise delivered.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/#organization\",\"name\":\"Slipstream LS\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/slipstream-life-sciences-mark.jpg\",\"contentUrl\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/slipstream-life-sciences-mark.jpg\",\"width\":1200,\"height\":1200,\"caption\":\"Slipstream LS\"},\"image\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/slipstreamls\\\/posts\\\/?feedView=all\"],\"description\":\"Slipstream is a life sciences technology partner focused on intelligent, compliant, and trusted execution across R&D, enterprise platforms, data, and operations. We help organizations accelerate research, optimize operations, and implement technology that keeps pace with life-changing missions in an increasingly complex regulatory environment.\",\"email\":\"info@slipstreamls.com\",\"telephone\":\"+1-267-705-4000\",\"legalName\":\"Slipstream IT, LLC\",\"foundingDate\":\"2020-01-01\",\"naics\":\"5415\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"501\",\"maxValue\":\"1000\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology > Slipstream LS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","og_locale":"fr_FR","og_type":"article","og_title":"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology","og_description":"Blue Bell, Pennsylvanie \u2013 10 juillet 2025 \u2013 Slipstream, partenaire technologique de confiance au service de l\u2019industrie pharmaceutique et biopharmaceutique, est fier d\u2019annoncer sa co-signature d\u2019une \u00e9tude r\u00e9volutionnaire sur la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire (HHT), r\u00e9cemment publi\u00e9e dans l\u2019American Journal of Hematology. L\u2019\u00e9tude, \u00ab Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia \u00bb, est […]","og_url":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","og_site_name":"Slipstream LS","article_modified_time":"2026-06-19T01:31:52+00:00","og_image":[{"width":809,"height":1080,"url":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","url":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","name":"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l'American Journal of Hematology > Slipstream LS","isPartOf":{"@id":"https:\/\/www.slipstreamls.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#primaryimage"},"image":{"@id":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","datePublished":"2026-03-02T21:32:21+00:00","dateModified":"2026-06-19T01:31:52+00:00","breadcrumb":{"@id":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#primaryimage","url":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","contentUrl":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","width":809,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.slipstreamls.com\/fr\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.slipstreamls.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Resources","item":"https:\/\/www.slipstreamls.com\/fr\/resources\/"},{"@type":"ListItem","position":3,"name":"Slipstream co-r\u00e9dige la premi\u00e8re \u00e9tude compl\u00e8te sur les co\u00fbts de la t\u00e9langiectasie h\u00e9morragique h\u00e9r\u00e9ditaire dans l’American Journal of Hematology"}]},{"@type":"WebSite","@id":"https:\/\/www.slipstreamls.com\/fr\/#website","url":"https:\/\/www.slipstreamls.com\/fr\/","name":"Slipstream","description":"Life sciences, accelerated. Expertise delivered.","publisher":{"@id":"https:\/\/www.slipstreamls.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.slipstreamls.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.slipstreamls.com\/fr\/#organization","name":"Slipstream LS","url":"https:\/\/www.slipstreamls.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.slipstreamls.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/03\/slipstream-life-sciences-mark.jpg","contentUrl":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/03\/slipstream-life-sciences-mark.jpg","width":1200,"height":1200,"caption":"Slipstream LS"},"image":{"@id":"https:\/\/www.slipstreamls.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/slipstreamls\/posts\/?feedView=all"],"description":"Slipstream is a life sciences technology partner focused on intelligent, compliant, and trusted execution across R&D, enterprise platforms, data, and operations. We help organizations accelerate research, optimize operations, and implement technology that keeps pace with life-changing missions in an increasingly complex regulatory environment.","email":"info@slipstreamls.com","telephone":"+1-267-705-4000","legalName":"Slipstream IT, LLC","foundingDate":"2020-01-01","naics":"5415","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"501","maxValue":"1000"}}]}},"_links":{"self":[{"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/resource\/3715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/media\/3100"}],"wp:attachment":[{"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/media?parent=3715"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/resource_type?post=3715"},{"taxonomy":"business_need","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/business_need?post=3715"},{"taxonomy":"service_type","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/service_type?post=3715"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/fr\/wp-json\/wp\/v2\/topic?post=3715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}